AstraZeneca, Saint Luke’s begin Phase 3 Farxiga trial in COVID-19 patients
Farxiga is an oral, once-daily sodium-glucose cotransporter 2 (SGLT2) inhibitor used for the treatment of insufficiently controlled T2D
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
24 Apr 20
Farxiga is an oral, once-daily sodium-glucose cotransporter 2 (SGLT2) inhibitor used for the treatment of insufficiently controlled T2D
24 Apr 20
ChAdOx1 nCoV-19 has been developed through genetically modifying ChAdOx1 virus, a weakened version of common cold virus
The experience of adapting to new challenges for the cold chain may well prove vital when pharmaceutical companies…
FacilitiesPharmaceuticals and MedicinesClinical supplies and logistics
23 Apr 20
Kymriah has been previously approved for pediatric and young adult acute lymphoblastic leukemia (ALL), and adult diffuse large…
23 Apr 20
BioNTech and Pfizer have joined forces to develop BNT162, the vaccine that has potential to prevent the COVID-19…
22 Apr 20
The company has partnered with Advanced Diagnostics Healthcare (ADH) at River Oaks Hospital and Clinics to conduct the…
17 Apr 20
Convalescent plasma is an antibody-based product, developed from blood donated by people who have recovered from the disease…
17 Apr 20
The new data includes interim exploratory results from the real-world TELESCOPE trial, real-world PERISCOPE study and other long…
15 Apr 20
Sanofi and GSK are planning to begin a phase 1 clinical trial in the second half of 2020,…
15 Apr 20
The trial, called CALAVI, evaluates the effect of Calquence on the exaggerated immune response of patients hospitalised with…